PMC:4822111 / 8738-9173 JSONTXT

{"project":"2_test","denotations":[{"id":"27066091-21989327-56335791","span":{"begin":431,"end":433},"obj":"21989327"}],"text":"Eribulin in the Asian patient population\nThe only clinical trial data for eribulin in the Asian breast-cancer-patient population comes from a phase II, multicenter, single-arm study of 80 Japanese mBC patients who were treated with eribulin as third- and later-line chemotherapy. The ORR was 21.3% (95% CI, 12.9%–31.8%; all partial responses). Based on an independent review, 37.5% of the patients in the study had stable disease [20]."}